Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dashan Ai

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Frontiers in Oncology|November 19, 2021
Cancer of Pharyngoesophageal Junction: A Different Subtype From Hypopharyngeal and Cervical Esophageal Cancer?Xiaoyu Li, Dashan Ai, Yun Chen, et al.
Eclinicalmedicine|February 15, 2024
Induction sintilimab and chemotherapy followed by concurrent chemoradiotherapy for locally advanced esophageal cancer: a proof-of-concept, single-arm, multicenter, phase 2 trialDashan Ai, Shengnan Hao, Wenbin Shen, et al.
The Lancet. Gastroenterology & Hepatology|November 19, 2023
Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trialQi Liu, Junqiang Chen, Yu Lin, et al.
Radiation Oncology (London, England)|July 29, 2022
Dose escalation based on <sup>18</sup>F-FDG PET/CT response in definitive chemoradiotherapy of locally advanced esophageal squamous cell carcinoma: a phase III, open-label, randomized, controlled trial (ESO-Shanghai 12)Hongcheng Zhu, Qiufang Liu, Hao Xu, et al.
JAMA Network Open|February 21, 2022
Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer: A Randomized Clinical TrialDashan Ai, Jinjun Ye, Shihong Wei, et al.
Future Oncology (London, England)|March 4, 2026
Precision palliative care in advanced/recurrent esophageal cancer patients treated with anti-PD-1/PD-L1 immunotherapy (ESO-Shanghai 25): a randomized, phase III TrialShengnan Hao, Xiaomin Wang, Huiping Ding, et al.
BMJ Open|October 23, 2018
Comparison of paclitaxel in combination with cisplatin (TP), carboplatin (TC) or fluorouracil (TF) concurrent with radiotherapy for patients with local advanced oesophageal squamous cell carcinoma: a three-arm phase III randomized trial (ESO-Shanghai 2)Dashan Ai, Yun Chen, Qi Liu, et al.
Nature Communications|November 17, 2017
Comparative genomic analysis of esophageal squamous cell carcinoma between Asian and Caucasian patient populationsJiaying Deng, Hu Chen, Daizhan Zhou, et al.
Future Oncology (London, England)|July 30, 2025
ESO-Shanghai 20: phase III clinical trial of anti-PD-1 therapy with local intervention for oligometastatic ESCCGuangmin Mao, Zhuocheng Xin, Qingsong Fan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2025
Radiation Dose-Volume Effects on Negative Tumor-Draining Lymph Nodes Affected T-cell Activation and Prognosis in Esophageal Cancer with ChemoradiotherapyIhsuan Tseng, Yun Chen, Dashan Ai, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Frontiers in Oncology|November 19, 2021
Cancer of Pharyngoesophageal Junction: A Different Subtype From Hypopharyngeal and Cervical Esophageal Cancer?Xiaoyu Li, Dashan Ai, Yun Chen, et al.
Eclinicalmedicine|February 15, 2024
Induction sintilimab and chemotherapy followed by concurrent chemoradiotherapy for locally advanced esophageal cancer: a proof-of-concept, single-arm, multicenter, phase 2 trialDashan Ai, Shengnan Hao, Wenbin Shen, et al.
The Lancet. Gastroenterology & Hepatology|November 19, 2023
Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trialQi Liu, Junqiang Chen, Yu Lin, et al.
Radiation Oncology (London, England)|July 29, 2022
Dose escalation based on <sup>18</sup>F-FDG PET/CT response in definitive chemoradiotherapy of locally advanced esophageal squamous cell carcinoma: a phase III, open-label, randomized, controlled trial (ESO-Shanghai 12)Hongcheng Zhu, Qiufang Liu, Hao Xu, et al.
JAMA Network Open|February 21, 2022
Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer: A Randomized Clinical TrialDashan Ai, Jinjun Ye, Shihong Wei, et al.
Future Oncology (London, England)|March 4, 2026
Precision palliative care in advanced/recurrent esophageal cancer patients treated with anti-PD-1/PD-L1 immunotherapy (ESO-Shanghai 25): a randomized, phase III TrialShengnan Hao, Xiaomin Wang, Huiping Ding, et al.
BMJ Open|October 23, 2018
Comparison of paclitaxel in combination with cisplatin (TP), carboplatin (TC) or fluorouracil (TF) concurrent with radiotherapy for patients with local advanced oesophageal squamous cell carcinoma: a three-arm phase III randomized trial (ESO-Shanghai 2)Dashan Ai, Yun Chen, Qi Liu, et al.
Nature Communications|November 17, 2017
Comparative genomic analysis of esophageal squamous cell carcinoma between Asian and Caucasian patient populationsJiaying Deng, Hu Chen, Daizhan Zhou, et al.
Future Oncology (London, England)|July 30, 2025
ESO-Shanghai 20: phase III clinical trial of anti-PD-1 therapy with local intervention for oligometastatic ESCCGuangmin Mao, Zhuocheng Xin, Qingsong Fan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2025
Radiation Dose-Volume Effects on Negative Tumor-Draining Lymph Nodes Affected T-cell Activation and Prognosis in Esophageal Cancer with ChemoradiotherapyIhsuan Tseng, Yun Chen, Dashan Ai, et al.
Pageof 3